VEGF、EGF在再生障碍性贫血患者血清中的表达及意义

目的 检测再生障碍性贫血患者血清中血管内皮生长因子(VEGF)与表皮生长因子(EGF)的浓度,探讨VEGF和EGF在再生障碍性贫血患者血液中的表达及二者之间的关系和意义.方法 应用酶联免疫技术(ELISA法)检测20例再障患者及40名健康人血清中VEGF和EGF浓度.结果 20例再生障碍性贫血患者血清VEGF的含量为50.5±34.8pg/ml,对照组血清VEGF的含量为108.5±50.6 pg/ml,两组比较有统计学意义(P＜0.05).20例再生障碍性贫血患者血清EGF含量为0.15±0.11 μg/L,40例正常对照组血清EGF含量为0.76±0.80 μg/L.结论 再生障碍性贫血患者血清VEGF、EGF浓度显著低于健康对照组,且二者呈显著正相关.     

保留齿状线加皮桥重建闭合切口治疗环状混合痔32例疗效观察

目的探讨保留齿状线加皮桥重建闭合切口治疗环状混合痔的可行性及疗效。方法治疗组选用保留齿状线加皮桥重建闭合切口32例，与对照组采用传统外剥内扎治疗34例在术后疼痛、水肿、出血、痔残留等并发症及住院时间、愈合时间等方面进行比较。结果治疗组在术后疼痛、水肿、出血、痔残留等及住院时间、愈合时间等方面均优于对照组。结论保留齿状线加皮桥重建闭合切口治疗环状混合痔安全、有效、可行。     

PFT-α对结肠上皮细胞凋亡和周期的影响及机制探讨

目的探讨p53抑制剂（p-fifty three inhibitor—alpha，PFT-α）对结肠上皮细胞凋亡、周期的影响及机制。研究PFT-α对热化疗损伤结肠上皮细胞的影响。方法顺铂联合温热处理原代培养结肠七皮细胞30min，对比加入不同浓度PFT-α后，Annexin V—FITC／PI染色，流式细胞仪检测细胞凋亡。PI染色检测细胞周期。Western blot检测结肠上皮细胞Cyclin B1和Cdc2（Tyr15）表达。结果不同浓度PFT-α作用于热化疗处理的结肠上皮细胞后，细胞凋亡率下降且呈剂量依赖性。流式细胞仪细胞周期分析显示在运用PFT-α后，结肠上皮细胞的G2／M延长，CyclinB1和Cde2（Tyr15）蛋白表达随PFT—α的剂量升高而逐渐增强。结论PFT-α可能通过促进CyclinB1蛋白表达，Cde2（Tyr15）磷酸化水平升高，降低CyclinB1／Cde2活性，细胞停滞于G2／M期，减轻热化疗对结肠上皮细胞的损伤。     

18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma.

Conventional work-up (CWU) with chest radiography, abdominal ultrasonography, and skeletal scintigraphy has limited value in M staging of nonkeratinizing nasopharyngeal carcinoma (NPC). Our aim was to evaluate whether (18)F-FDG PET could replace CWU by comparing their diagnostic efficacies. METHODS: Patients with histologically proven nonkeratinizing NPC and no prior treatment were prospectively enrolled. All study participants underwent CWU and (18)F-FDG PET for primary M staging. Distant metastasis was considered to be present if there was any reliable evidence identified within 1 y after diagnosis. The comparative diagnostic efficacies of (18)F-FDG PET, CWU, and the combination of (18)F-FDG PET and CWU (PET+CWU) were evaluated using the areas under the receiver-operating-characteristic (ROC) curves. RESULTS: Sixty-one (20.3%) of 300 eligible patients were found to have distant metastases. On a patient-based analysis, (18)F-FDG PET was found to be more effective than CWU (P < 0.001), whereas it was equally effective with PET+CWU (P = 0.130). On region-based analyses, (18)F-FDG PET was more effective than skeletal scintigraphy and chest radiography for detecting bone metastases (P < 0.001) and chest metastases (P < 0.001), respectively. (18)F-FDG PET and abdominal ultrasound were equally effective for detecting hepatic metastases (P = 0.127). On region-based analyses, the combination of (18)F-FDG PET and CWU did not yield any noticeable increase in diagnostic efficacy. CONCLUSION: (18)F-FDG PET can replace CWU in primary M staging of nonkeratinizing NPC.